...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Blood Medicine >Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
【24h】

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

机译：关键评估重组活化因子VII在血友病患者中使用抑制剂的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Hemophilia patients with inhibitors faced the constraint of inadequate treatment for several years before the era of recombinant factor VIIa (rFVII). Initially, rFVIIa was used in the compassionate-use programs. After a worldwide license was issued, more than 1.5 million doses were administered. Bleeding of joints and muscles was controlled effectively by means of an early home treatment program, with either a standard dose of 90 μg/kg every 2 to 3 hours for a few doses or a single dose of 270 μg/kg. For more serious bleeding episodes or minor surgery, an initial dose of 90 μg/kg was given every 2 hours for 24 to 48 hours followed by increased intervals of 3 to 6 hours according to the severity of bleeding and efficacy of bleeding control. In cases of major surgery such as orthopedic procedures, the same regimen can be applied except for a higher initial dose of 120 to 180 μg/kg. However, increasing the dose should be considered if there are unexpected bleeding complications since the half-life and clearance of rFVIIa differ between individuals. In addition, prophylaxis is administered to a small number of patients. Finally, the reported thromboembolic events found in hemophilia patients with inhibitors receiving rFVIIa are extremely low, much less than 1%.
机译：摘要：带有抑制剂的血友病患者在重组因子VIIa（rFVII）时代来临之前面临着治疗不足的局限。最初，rFVIIa用于同情使用程序。在全球范围内颁发许可证后，已施用了超过150万剂。通过早期的家庭治疗程序，可以有效地控制关节和肌肉的出血，标准剂量为每2至3小时90μg/ kg，持续数次，或单剂量270μg/ kg。对于更严重的出血事件或较小的手术，根据出血的严重程度和出血控制的有效性，每2小时给予一次90μg/ kg的初始剂量，持续24至48小时，然后增加3至6小时的间隔。对于大手术（例如整形外科手术），可以采用相同的治疗方案，但初始剂量较高，为120至180μg/ kg。但是，如果出现意外的出血并发症，则应考虑增加剂量，因为rFVIIa的半衰期和清除率因人而异。另外，对少数患者进行预防。最后，在接受rFVIIa抑制剂治疗的血友病患者中发现的血栓栓塞事件极低，远远少于1％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号